Fully Human Anti-Cd19/Cd22 Dual Target Chimeric Antigen Receptor Autologous T Cell

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →

Nanjing IASO Biotechnology Co., Ltd.Cell therapyPhase 1/2

—

Rating in progress

Fully Human Anti-Cd19/Cd22 Dual Target Chimeric Antigen Receptor Autologous T Cell in B-Cell Non-Hodgkin Lymphoma is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.

Methodology v0.2 · Active